ALBERT

Beschreibung: Grafting of vegetable plants is done primarily to reduce the potential for damage caused by soil-borne diseases. Most of the watermelons (Citrullus) grown in the Mediterranean Basin, including in Israel, are grafted, mainly on interspecific hybrid pumpkin (Cucurbita) rootstocks. Biblical law (Leviticus 19:19) does not allow intergeneric grafting, so in recent years, great efforts have been made in Israel to find or breed watermelon rootstocks. Both interspecific and intergeneric grafting can have negative or positive effects on fruit yield and quality after harvest. The inconsistencies in fruit quality and shelf-life parameters can be attributed to differences in production environments. However, many farmers are grafting and planting the same rootstock-scion combination all over the country, regardless of local soil, water, and climactic conditions. We studied the effect of similar rootstock-scion combinations on watermelon yield and fruit quality in three regions of Israel differing in soil type and altitude. Fruit-quality parameters were evaluated after 4 days at 21 °C (local marketing simulation). Fruit quality was significantly affected, mainly by the growing region, based on factorial analysis, but also by rootstock-scion combination, regardless of rootstock vigor. Therefore, the best rootstock-scion combination needs to be found and adopted for each growing region. Grafting was essential for watermelon crop survival in contaminated soils and improved both plant performance and postharvest fruit quality, but was not a factor in non-contaminated soils.

Beschreibung: Antimatter continues to intrigue physicists because of its apparent absence in the observable Universe. Current theory requires that matter and antimatter appeared in equal quantities after the Big Bang, but the Standard Model of particle physics offers no quantitative explanation for the apparent disappearance of half the Universe. It has recently become possible to study trapped atoms of antihydrogen to search for possible, as yet unobserved, differences in the physical behaviour of matter and antimatter. Here we consider the charge neutrality of the antihydrogen atom. By applying stochastic acceleration to trapped antihydrogen atoms, we determine an experimental bound on the antihydrogen charge, Qe, of |Q| 〈 0.71 parts per billion (one standard deviation), in which e is the elementary charge. This bound is a factor of 20 less than that determined from the best previous measurement of the antihydrogen charge. The electrical charge of atoms and molecules of normal matter is known to be no greater than about 10(-21)e for a diverse range of species including H2, He and SF6. Charge-parity-time symmetry and quantum anomaly cancellation demand that the charge of antihydrogen be similarly small. Thus, our measurement constitutes an improved limit and a test of fundamental aspects of the Standard Model. If we assume charge superposition and use the best measured value of the antiproton charge, then we can place a new limit on the positron charge anomaly (the relative difference between the positron and elementary charge) of about one part per billion (one standard deviation), a 25-fold reduction compared to the current best measurement.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Ahmadi, M -- Baquero-Ruiz, M -- Bertsche, W -- Butler, E -- Capra, A -- Carruth, C -- Cesar, C L -- Charlton, M -- Charman, A E -- Eriksson, S -- Evans, L T -- Evetts, N -- Fajans, J -- Friesen, T -- Fujiwara, M C -- Gill, D R -- Gutierrez, A -- Hangst, J S -- Hardy, W N -- Hayden, M E -- Isaac, C A -- Ishida, A -- Jones, S A -- Jonsell, S -- Kurchaninov, L -- Madsen, N -- Maxwell, D -- McKenna, J T K -- Menary, S -- Michan, J M -- Momose, T -- Munich, J J -- Nolan, P -- Olchanski, K -- Olin, A -- Povilus, A -- Pusa, P -- Rasmussen, C O -- Robicheaux, F -- Sacramento, R L -- Sameed, M -- Sarid, E -- Silveira, D M -- So, C -- Tharp, T D -- Thompson, R I -- van der Werf, D P -- Wurtele, J S -- Zhmoginov, A I -- England -- Nature. 2016 Jan 21;529(7586):373-6. doi: 10.1038/nature16491.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Physics, University of Liverpool, Liverpool L697ZE, UK. ; Department of Physics, University of California at Berkeley, Berkeley, California 94720-7300, USA. ; Centre de Recherches en Physique des Plasmas (CRPP), Ecole Polytechnique Federale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. ; School of Physics and Astronomy, University of Manchester, Manchester M13 9PL, UK. ; Cockcroft Institute, Sci-Tech Daresbury, Warrington WA4 4AD, UK. ; Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, UK. ; Physics Department, European Organisation for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland. ; Department of Physics and Astronomy, York University, Toronto, Ontario M3J 1P3, Canada. ; Instituto de Fisica, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-972, Brazil. ; Department of Physics, Swansea University, Swansea SA2 8PP, UK. ; Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada. ; Department of Physics and Astronomy, Aarhus University, DK-8000 Aarhus C, Denmark. ; TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada. ; Department of Physics, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada. ; Department of Physics, Stockholm University, SE-10691, Stockholm, Sweden. ; Department of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada. ; Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia V8P 5C2, Canada. ; Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA. ; Soreq Nuclear Research Center, Yavne, 81800, Israel. ; Department of Physics and Astronomy, University of Calgary, Calgary, Alberta T2N 1N4, Canada. ; ATAP, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/26791725" target="_blank"〉PubMed〈/a〉

Beschreibung: Observation of the 1S–2S transition in trapped antihydrogen Nature 541, 7638 (2017). doi:10.1038/nature21040 Authors: M. Ahmadi, B. X. R. Alves, C. J. Baker, W. Bertsche, E. Butler, A. Capra, C. Carruth, C. L. Cesar, M. Charlton, S. Cohen, R. Collister, S. Eriksson, A. Evans, N. Evetts, J. Fajans, T. Friesen, M. C. Fujiwara, D. R. Gill, A. Gutierrez, J. S. Hangst, W. N. Hardy, M. E. Hayden, C. A. Isaac, A. Ishida, M. A. Johnson, S. A. Jones, S. Jonsell, L. Kurchaninov, N. Madsen, M. Mathers, D. Maxwell, J. T. K. McKenna, S. Menary, J. M. Michan, T. Momose, J. J. Munich, P. Nolan, K. Olchanski, A. Olin, P. Pusa, C. Ø. Rasmussen, F. Robicheaux, R. L. Sacramento, M. Sameed, E. Sarid, D. M. Silveira, S. Stracka, G. Stutter, C. So, T. D. Tharp, J. E. Thompson, R. I. Thompson, D. P. van der Werf & J. S. Wurtele The spectrum of the hydrogen atom has played a central part in fundamental physics over the past 200 years. Historical examples of its importance include the wavelength measurements of absorption lines in the solar spectrum by Fraunhofer, the identification of transition lines by Balmer, Lyman and others, the empirical description of allowed wavelengths by Rydberg, the quantum model of Bohr, the capability of quantum electrodynamics to precisely predict transition frequencies, and modern measurements of the 1S–2S transition by Hänsch to a precision of a few parts in 1015. Recent technological advances have allowed us to focus on antihydrogen—the antimatter equivalent of hydrogen. The Standard Model predicts that there should have been equal amounts of matter and antimatter in the primordial Universe after the Big Bang, but today’s Universe is observed to consist almost entirely of ordinary matter. This motivates the study of antimatter, to see if there is a small asymmetry in the laws of physics that govern the two types of matter. In particular, the CPT (charge conjugation, parity reversal and time reversal) theorem, a cornerstone of the Standard Model, requires that hydrogen and antihydrogen have the same spectrum. Here we report the observation of the 1S–2S transition in magnetically trapped atoms of antihydrogen. We determine that the frequency of the transition, which is driven by two photons from a laser at 243 nanometres, is consistent with that expected for hydrogen in the same environment. This laser excitation of a quantum state of an atom of antimatter represents the most precise measurement performed on an anti-atom. Our result is consistent with CPT invariance at a relative precision of about 2 × 10−10.

Beschreibung: Introduction: Autologous Stem Cell Transplantation (ASCT) has become the cornerstone of managing relapsed lymphomas. However, its use in elderly patients or those with comorbidities is limited because of high regimen related toxicities (RRT). Several chemotherapy regimens have been suggested to minimize RRT while maintaining the antitumor effect. TECAM (Thiotepa 160 mg/m2 over 4 days , Etoposide and Cytarabine 800mg/m2 over 4 days, Cytoxan 60 mg/kg, and Melphalan 120 mg/m2 over 2 days) is a reduced toxicity modification for the commonly used BEAM protocol. Aim: This study aimed to compare the safety and efficacy or the TECAM regimen with that of its more intense BEAM counterpart. Methods: A retrospective cohort study of all patients who underwent ASCT for treatment of lymphoma with either BEAM or TECAM conditioning regimens at the Tel Aviv Medical Center between October 1999 and January 2014. We compared early (≤100 days) mortality, RRT rate, time to engraftment and length of hospitalization as well as overall and progression free survival. Results: A total of 146 patients (76 BEAM, 70 TECAM) were included in the analysis. Median follow up was 47 months. Patient treated with TECAM were older (54.5 vs. 45.5, p=0.001), and nearly 20% (n=13) of them had dose reductions (average 17±7%), as opposed to a single patient in the BEAM arm. Conversely, TECAM patients had a longer time interval from first diagnosis to transplant (22 vs. 13 months, p

Beschreibung: Introduction: Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase, is an established therapeutic agent in a variety of B-cell lymphoproliferative disorders. Ibrutinib induces platelet dysfunction and concurrent treatment with ibrutinib and warfarin was shown to significantly increase the risk of bleeding. The current study was designed to investigate the safety of direct oral anticoagulants (DOACs) in patients receiving ibrutinib, considering their expanding employment together with the lack of data regarding their safety in patients receiving ibrutinib. Methods: We conducted a retrospective cohort study to evaluate risks of major bleeding in patients with B-cell lymphoproliferative disorders (CLL, MCL, DLBCL, MZL or WM) that were treated with ibrutinib and DOACs but without concurrent antiplatelet therapy, between January 2010 and October 2018 in 5 participating centers. Patient medical charts were reviewed for demographic parameters, comorbidities, ibrutinib dosage, DOACs dosage (including the adjustment for renal function), blood count and chemistry tests, bleeding site and grade. Results: The study included 30 patients, median age at starting concurrent administration of ibrutinib and DOACs was 71.58 years (range 50.9-88.2). Most patients were treated for CLL (n=18, 60%) and MCL (n=8, 26%). The most common daily doses of ibrutinib were 420 mg and 560 mg in 63.3% and 30% of patients respectively. None of the patients received an additional antiplatelet agent. Twenty-three patients were treated with apixaban (76.7%), 4 with rivaroxaban (13.3%) and 3 (10%) with dabigatran. The main indications for DOACs were atrial fibrillation and VTE (venous thromboembolism). The median follow-up after initiation of the ibrutinib-DOAC combination was 13.4 months (range 1.8-47.9 months). Bleeding was reported in 22 patients (73.3%), mostly mucocutaneous (n=12, 40%) and gastrointestinal tract (n=7, 23.3%), followed by CNS bleeding (n=4, 13.3%). Mucocutaneous bleedings were all grade 1-2 and gastrointestinal tract and CNS bleeding events were grade 1-4. Major bleeding events, defined as grade 3 or 4, occurred in 5 patients (16.6%) and did not result in death of any of the patients. The median time for bleeding following ibrutinib-DOAC initiation was 5.6 months. Over a follow-up period of 21 months of combined treatment, the incidence of bleeding events (of all grades) increased to 75% (Figure 1). Incidence of bleeding events (including all grades) was quite similar between all DOAC subtypes (73.9% with apixaban, 75% with rivaroxaban and 66.7% with dabigatran). No statistically significant predictors for increased risk of bleeding in patients receiving ibrutinib combined with DOACs were detected. Ibrutinib was stopped in 8 patients (26.7%) due to grade 1 to 4 bleeding events and was re-initiated in 6 patients, resulting in recurrent grade 3 and 4 bleeding events in 2 patients. Conclusions: Concurrent administration of DOACs and ibrutinib appears to be feasible. However, risk of bleeding is not neglectable, and treatment resumption in patients that experienced a significant bleeding event should be considered with caution. Disclosures Arnason: Celgene/Juno: Consultancy; Regeneron Pharmaceuticals, Inc.: Consultancy. Herishanu:Roche: Honoraria; AbbVie: Honoraria; Janssen: Honoraria.

Beschreibung: Introduction The therapeutic options for diffuse large cell B cell lymphoma (DLBCL) patients (pts) that fail to respond/relapse after≥2 treatment regimens are limited. The SCHOLAR-1 study reported an overall response/ complete remission (ORR/CR) rates of 26%/ 7% with a median overall survival (OS) of 6.3 months in chemorefractory and early relapsing DLBCL pts. Polatuzumab vedotin (Pola) is a conjugated antibody that delivers the microtubule inhibitor MMAE to CD79b-expressing cells. Polatuzumab administered in combination with Bendamustine-Rituximab (P-BR) has been recently approved by the FDA for pts with relapsed/refractory (R/R) DLBCL that failed to respond≥2 prior therapies. The current study investigated the tolerability and efficacy of Pola mainly with BR, in DLBCL pts, treated through a compassionate program after failing ≥2 prior regimens. Methods Data of all pts with consecutive R/R DLBCL, treated with Pola-BR or Pola-R (2-8 cycles) in 11 Israeli centers between 6/2018 and -5/2019 were analyzed. Inclusion criteria for this study were: R/R DLBCL (denovo and transformed follicular lymphoma [t-FL]), age ≥ 18 years, ≥ 2 prior treatments. We evaluated pt characteristics, treatment details and toxicities, overall response and CR rates, progression free survival (PFS) and OS. Cox regression model was used to define factors affecting outcomes. Results 34 patients- (denovo DLBCL, n=24 and t-FL, n=10 ⌈50% -non CGB and 50% - GCB type⌉) were included. Median age at Pola administration was 65.5 (range 60-72) years. Stage ≥3 disease was recorded in 88% and IPI ≥3 in 73.5%. Median prior lines was 3 (range 3-5); including anthracyclines and rituximab in 100% and cisplatin-based regimens in 91%. 32% relapsed after ASCT and 9% after CART infusion. 53% had primary refractory disease, 29% had refractory relapse and 18% had prior sensitive relapse. 22 pts received Pola-B, mostly with Rituximab (n=19), and 12 received Pola-R. In 5 pts, Pola-based regimen was used as a bridge for Allo SCT (all responded CR, n=4 and PR, n=1) and in 6 as a bridge to CARTs (all responded CR n=1, PR n=2, SD n=3). Median number of Pola B cycles was 3 (3-5) and median Pola-R cycles was 4 (3-6). Median B dose per cycle was 90 mg/m2 (45-90). GCSF was used in 47%. Early treatment discontinuation due to progressive disease (PD) occurred in 8 (23%) of the entire cohort: 23% of Pola-B pts and 25% of Pola-R pts. Safety: Hematological AEs grade 3-4, reported with Pola- B vs Pola-R were: neutropenia (45.5.% vs 33%), thrombocytopenia (25% vs 8%) and anemia (23% vs 17%). Infections were recorded in 41% and 36% of Pola-B pts and Pola-R respectively. Neutropenic fever was reported in 36% in Pola-B pts and none in Pola-R. Pulmonary infections were recorded in 33.3% and 27.3% of Pola-B and Pola-R pts respectively, resulting in death in one pt. Peripheral neuropathy occurred in 18% of Pola- B pts (grade ≤2) vs 8% with Pola -R. Hospitalization due to AEs was recorded in 41% of Pola-B vs 25% of Pola-R. Pola dose reduction due to AE was reported in 1 pt (8%) in the Pola-R. Efficacy: ORR for the entire cohort was 65%, including 38% CRs and 27% PRs. 12% pts attained SD and 23% experienced PD. ORR was higher in non-GCB than in GCB pts 80% vs 43% (p=0.036). Median follow up of the entire cohort from Pola administration was 4.4 months (range 0.6-11.4). 6 months projected OS and PFS were 83% and 63%, respectively. Post Pola treatment in pts that failed to respond/Relapsed post pola: 8 patients had PD; 3 died from progression, 1-CART, 1-Allo SCT, 2-paliative care and 1-unknown. Additional 5 pts progressed during follow up; 4-CART and 1-palliative care. 1 patient continues Pola treatment after achieving SD. Univariate analysis for factors predicting PFS and OS GCB type (HR-1.816, P=0.055), Primary refractory vs relapsed disease (HR-1.507, p=0.049) and a higher number of prior lines since diagnosis (HR-1.35, p=0.079) tended to be associated with shorter time to progression. T-FL vs denovo DLBCL was associated with decreased OS (p=0.008). Data of 60 patients, including pts treated recently, therefore, not evaluable at the time of abstract submission, would be presented at ASH. Conclusions The toxicity of Pola-based regimen was relatively low. Pola based treatment provided an encouraging PFS and OS in pts with R/R DLBCL that failed to respond ≥2 prior therapies, treated in a real-life setting. Primary refractory disease, higher number prior lines and t-FL vs denovo DLBCL were associated with inferior outcome. Figure Disclosures Herishanu: Roche: Honoraria; AbbVie: Honoraria; Janssen: Honoraria.